Sino Medical Sciences Technology Inc. (688108): Successful bidding in centralized procurement aids in performance recovery, and technological innovation builds a differentiated moat.

Sino medical sciences technology inc. focuses on coronary intervention and neuro intervention. It is an international company rooted in China, targeting the global market, and specializing in the research, development, production, and sales of high-end medical instruments. The demand in the coronary intervention market is flourishing, and centralized procurement supports the company's performance recovery.

china merchantsDec 4 14:17

sino medical sciences technology inc. (688108): centralized procurement helps increase the volume of coronary products. The follow-up results of the new drug-eluting stent are impressive.

Event: Recently, the company released the third quarter report for 2024: The company achieved revenue of 0.318 billion yuan in the first three quarters of 2024, a year-on-year increase of 30.20%, mainly due to a significant increase in sales of coronary products. Net income attributable to equity holders -

the pacific securitiesNov 11 18:32

Express News | sino medical sciences technology inc.: The company's products have obtained registration certificates in Peru.

BreakingsNov 8 15:37

Sano Medical Science & Technology Co., Ltd. Third Quarter Report 2024

SZSIOct 30 00:00 · Announcements

sino medical sciences technology inc. (688108): Deeply cultivating the vascular intervention field for more than ten years, innovation is expected to bring harvest.

Shenjie, dual-track driven coronary artery molding, innovative medical devices moving towards globalization. Sino Medical Sciences Technology Inc. was established in 2007, the core team focusing on high-value intervention devices field for over 15 years, forming a dual-track drive in neurointervention and cardiovascular coronary artery business, drug elution

Huayuan SecuritiesOct 21 11:26

Sino Medical Sciences Technology Inc. (688108): Coronary business maintains high-speed growth, innovative single product for neurointervention is about to be certified.

The company's performance in the first half of 2024 meets expectations, with rapid growth in coronary artery business. The core product HT Supreme coronary stent is about to be approved in the US market. The future development trend of neurointervention business is promising, with heavyweight products.

中信建投证券Sep 20 15:51